Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls
Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls
复制标题
血清中循环的 CUDR、LSINCT-5 和 PTENP1 长非编码 RNA 可区分胃癌患者与健康对照
DOI：
10.1002/ijc.29484
复制
发表时间：
2015-09-01
影响因子：
6.4
通讯作者：
Du, Xiang
中科院分区：
文献类型：
--
作者：
Dong, Lei;Qi, Peng;Du, Xiang
循环核酸检测是一种新兴的非侵入性诊断技术。然而，目前尚不清楚血清长非编码RNA(LncRNAs)是否是检测胃癌(GC)的新标记物。本研究采用逆转录定量聚合酶链式反应(RT-qPCR)检测110例GC患者、106例年龄、性别匹配的健康人和15例消化性溃疡患者血清中39个候选肿瘤相关基因，并用RT-qPCR方法对其进行验证和评价。对候选血清中lncRNAs的表达水平与GC患者的临床参数进行相关性分析。发现了一个包括CUDR、LSINCT-5和PTENP1在内的三个lncRNA特征，可能是胃癌的潜在诊断标志物。两组血清样品的受试者工作特征(ROC)曲线下面积分别为0.920和0.829。此外，血清Three-LncRNA特征的风险模型表明，健康样本可以与早期GC样本区分开来。血清中的3-lncRNA特征被确定为GC的诊断标志。这项工作可能有助于GC的检测，并为进一步研究血清lncRNAs在维持监测和预测预后方面的临床价值奠定基础。有什么新进展？某些长的非编码RNA(LncRNAs)可能参与肿瘤的发生或抑制，这引发了人们对它们作为癌症生物标志物的潜在服务的疑问。本研究作者系统地评价了血清可检测的lncRNAs对胃癌(GC)患者的诊断价值。逆转录、定量聚合酶链式反应鉴定出一个与GC相关的以CUDR、LSINCT-5和PTENP1为中心的三个lncRNA特征。三个lncRNA特征成功地区分了早期GC患者和健康受试者。这一发现为进一步研究血清lncRNAs在早期GC检测中的临床应用价值奠定了基础。
The examination of circulating nucleic acids (CNAs) is an emerging noninvasive diagnostic technique. However, it is unclear if serum long noncoding RNAs (lncRNAs) represent a novel marker to detect gastric cancer (GC). In this study, we measured 39 candidate cancer-associated lncRNAs by reverse transcription and quantitative polymerase chain reaction (RT-qPCR) in sera from 110 patients with GC, 106 age- and sex-matched healthy subjects and 15 patients with gastric peptic ulcer, markers were validated and assessed by RT-qPCR. The correlation of the expression levels of the candidate serum lncRNAs with clinical parameters of GC patients was performed. A three-lncRNA signature, including CUDR, LSINCT-5 and PTENP1, was identified that may be potential diagnostic marker for GC. The areas under the receiver operating characteristic (ROC) curve for this serum three-lncRNA signature were 0.920 and 0.829 for the two sets of serum samples. Moreover, a risk model for the serum three-lncRNA signature demonstrated that healthy samples can be distinguished from early GC samples. Three-lncRNA signature in serum was identified as diagnostic marker for GC. This work may facilitate the detection of GC and serve as the basis for further studies of the clinical value of serum lncRNAs in maintaining surveillance and forecasting prognosis.What's new? Certain long noncoding RNAs (lncRNAs) may be involved in oncogenesis or tumor suppression, raising questions about their potential service as cancer biomarkers. The authors of the present study systematically assessed the diagnostic value of serum-detectable lncRNAs for gastric cancer (GC) patients. Reverse transcription, quantitative PCR resulted in the identification of a GC-associated three-lncRNA signature centering on CUDR, LSINCT-5 and PTENP1. The three-lncRNA signature successfully distinguished between early-stage GC patients and healthy subjects. The findings warrant further investigation of the clinical utility of serum lncRNAs in the detection of early-stage GC.